Nuveen Asset Management LLC Has $73.17 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Nuveen Asset Management LLC reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,530,519 shares of the biopharmaceutical company's stock after selling 8,634 shares during the quarter. Nuveen Asset Management LLC owned about 1.20% of Halozyme Therapeutics worth $73,174,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HALO. Park Avenue Securities LLC raised its holdings in shares of Halozyme Therapeutics by 6.9% in the fourth quarter. Park Avenue Securities LLC now owns 12,439 shares of the biopharmaceutical company's stock worth $595,000 after acquiring an additional 801 shares during the last quarter. Empirical Asset Management LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth about $1,091,000. Diversify Wealth Management LLC increased its holdings in shares of Halozyme Therapeutics by 63.8% during the 4th quarter. Diversify Wealth Management LLC now owns 15,464 shares of the biopharmaceutical company's stock valued at $816,000 after acquiring an additional 6,025 shares during the last quarter. Diversify Advisory Services LLC lifted its position in shares of Halozyme Therapeutics by 9.3% during the 4th quarter. Diversify Advisory Services LLC now owns 5,825 shares of the biopharmaceutical company's stock worth $308,000 after buying an additional 494 shares during the period. Finally, Sugar Maple Asset Management LLC bought a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $373,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded up $0.48 on Wednesday, hitting $53.93. The company had a trading volume of 1,967,953 shares, compared to its average volume of 1,612,320. The company has a market cap of $6.65 billion, a PE ratio of 15.72, a PEG ratio of 0.42 and a beta of 1.26. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The business has a 50 day moving average of $60.39 and a 200 day moving average of $55.93. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. During the same quarter in the previous year, the firm earned $0.79 earnings per share. The business's quarterly revenue was up 35.2% compared to the same quarter last year. As a group, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

HALO has been the subject of several recent analyst reports. Morgan Stanley downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. JPMorgan Chase & Co. boosted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Benchmark cut Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $61.90.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the transaction, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. This trade represents a 1.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,697 shares of company stock valued at $1,276,552 in the last 90 days. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.